Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2434 • 2019 ACR/ARP Annual Meeting
Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Joong Kyong Ahn ¹, Jiwon Hwang² and Gi Hyeon Seo ³, ¹Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, Republic of Korea, ³Health Insurance Review and Assessment Service, Wonju, Republic of Korea
Background/Purpose: The development of lymphomas is one of the most serious complications of SjS but the incidence, prevalence and estimated risk of lymphoma in primary…
Abstract Number: 1455 • 2019 ACR/ARP Annual Meeting
B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Alice Mai¹, Yuriy Baglaenko ², Dario Ferri ³, Kieran Manion ⁴, Dennisse Bonilla ⁵, Arthur Bookman ⁶ and Joan Wither ⁷, ¹University of British Columbia Department of Rheumatology, Vancouver, Canada, ²Brigham Woman's Hospital, Boston, ³University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, Canada, ⁷University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease with an incompletely understood pathogenesis and heterogenous disease manifestations. Identifying cellular immune changes that may…
Abstract Number: 2416 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Stacey Dillon¹, Lawrence Evans ¹, Katherine Lewis ¹, Susan Bort ¹, Erika Rickel ¹, Jing Yang ¹, Martin Wolfson ¹, Kayla Susmilch ¹, Sherri Mudri ¹, Steven Levin ¹, Janhavi Bhandari ¹, Fariha Ahmed-Qadri ¹, Mark Rixon ¹, Jan Hillson ², Stanford Peng ¹ and Kristine Swiderek ¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Seattle, WI
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit simultaneously the…
Abstract Number: 2435 • 2019 ACR/ARP Annual Meeting
Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Andreas Goules ¹, Michael Voulgarelis ², Loukas Chatzis², Vasilis Pezoulas ³, Francesco Ferro ⁴, Saviana Gandolfo ⁵, Valentina Donati ⁶, Luca Quartuccio ⁷, Cathryn Scott ⁸, Ginevra De Marchi ⁹, Georgios Michalopoulos ¹, Aliki Venetsanopoulou ¹, Aristea Papageorgiou ¹, Dimitris Ziogas ¹, Marina Sikara ¹, Argyropoulou Ourania ¹, Clio Mavragani ¹, Dimitris fotiadis ¹⁰, Salvatore De Vita ⁵, Chiara Baldini ⁴ and Athanasios Tzioufas ², ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, athens, Greece, ²Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, GR45110, Ioannina, Greece, Ioannina, Greece, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁶University of Pisa, Pisa, ⁷Rheumatology Clinic, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁸Institute of Anatomic Pathology, Department of Medical Area, University of Udine, Udine, Italy. *equally contributed, Udine, Italy, ⁹Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy, ¹⁰Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Ioannina, Greece
Background/Purpose: Non-Hodgkin’s lymphomas (NHLs) may complicate primary Sjögren’s syndrome (pSS) with significant impact on morbidity and mortality among patients. A large cohort of SS associated…
Abstract Number: 1458 • 2019 ACR/ARP Annual Meeting
Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren’s Syndrome
Takeshi Yoshida¹, Hiroyuki Nodera ², Yoshitaka Kumon ³ and Hiroki Mizukami ⁴, ¹Chikamori Hospital, Kochi, Japan, ²Kanazawa Medical University, Kanazawa, Japan, ³Chikamori Hospital, Kochi, ⁴Hirosaki University, Hirosaki, Japan
Background/Purpose: 6% of primary Sjögren's syndrome (pSS) patients manifests as various forms of neuropathies including painful sensory neuropathy (PSN), which can be treatable with immunomodulatory drugs such…
Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Xavier Mariette¹, Michele Bombardieri ², Ilias Alevizos ³, Rachel Moate ⁴, Barbara Sullivan ⁵, Ghaith Noaiseh ⁶, Marika Kvarnström ⁷, William Rees ³, Liangwei Wang ³ and Gabor Illei ³, ¹Université Paris-Sud, Paris, France, Paris, Centre, France, ²Queen Mary University of London, London, UK, London, United Kingdom, ³Viela Bio, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Cambridge, UK, Cambridge, United Kingdom, ⁵Amgen Inc., South San Francisco, CA, USA, South San Francisco, CA, ⁶University of Pittsburgh, PA, USA, Pittsburgh, PA, ⁷Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…
Abstract Number: 2436 • 2019 ACR/ARP Annual Meeting
The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention
Salvatore De Vita¹, Saviana Gandolfo ¹, Chiara Baldini ², Miriam Isola ³, Michael Voulgarelis ⁴, Andreas Goules ⁴, Ginevra De Marchi ⁵, Marco Binutti ¹, Sara Zandonella Callegher ⁵, Francesco Ferro ², Claudio Battistella ³, Loukas Chatzis ⁴ and Athanasios Tzioufas ⁴, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ³Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁴Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy
Background/Purpose: Since the risk of B-cell non-Hodgkin’s lymphoma (NHL) evolution is increased in primary Sjögren’s syndrome (pSS), its prevention represents a relevant therapeutic end-point. A…
Abstract Number: 1459 • 2019 ACR/ARP Annual Meeting
Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients
Soledad Retamozo¹, Nihan Acar-Denizli ², Astrid Rasmussen ³, Ildiko Fanny Horváth ⁴, Chiara Baldini ⁵, Roberta Priori ⁶, Pulukool Sandhya ⁷, Gabriela Hernandez-Molina ⁸, Berkan Armagan ⁹, SONJA PRAPROTNIK ¹⁰, Marika Kvarnstrom ¹¹, Roberto Gerli ¹², Agata Sebastian ¹³, Roser Solans-Laqué ¹⁴, Maureen Rischmueller ¹⁵, Sandra G. Pasoto ¹⁶, Valeria Valim ¹⁷, Gunnel Nordmark ¹⁸, Aike Kruize ¹⁹, Takashi Nakamura ²⁰, Benedikt Hofauer ²¹, Roberto Giacomelli ²², Virginia Fernandes Moça Trevisani ²³, Valérie Devauchelle Pensec ²⁴, Fabiola Atzeni ²⁵, Tamer A Gheita ²⁶, Sandra Consani-Fernández ²⁷, Antonia Szántó ²⁸, Kathy Sivils ³, Angelina Gattamelata ²⁹, Debashish Danda ⁷, Levent Kilic ³⁰, Elena Bartoloni ¹², Stefano Bombardieri ³¹, Jorge Sánchez-Guerrero ³², Marie Wahren-Herlenius ¹¹, Xavier Mariette ³³, Manuel Ramos-Casals ³⁴ and Pilar Brito-Zerón ³⁵, ¹Instituto De Investigaciones En Ciencias De La Salud, Univ. Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina., Cordoba, Argentina, ²Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey., Istanbul, Turkey, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Oklahoma, OK, ⁴Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁶Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ⁷Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India., Vellore, India, ⁸Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁹Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ¹⁰Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia., LJUBLJANA, Slovenia, ¹¹Department of Medicine, Solna, Division of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Stockholm, Sweden, ¹²Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ¹³Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Poland, Wroclaw, Poland, ¹⁴Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ¹⁵Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, ¹⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ¹⁷Department of Medicine, Federal University of Espírito Santo, Vitória, Brazil., Vitória, Brazil, ¹⁸Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands, Utrecht, Netherlands, ²⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Nagasaki, Japan, ²¹Otorhinolaryngology, Head and Neck Surgery, Technical University Munich, Munich, Germany., Munich, Germany, ²²Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ²³Department of Evidence-Based Medicine, Brazilian Cochrane Centre, Federal University of São Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, ²⁴University Hospital of Brest, Brest, France, ²⁵Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ²⁶Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt., Cairo, Egypt, ²⁷Internal Medicine, Hospital Maciel, Montevideo, Uruguay. Universidad de la República (UdelaR) , Montevideo, Uruguay., Montevideo, Uruguay, ²⁸Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary, ²⁹Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy, Rome, Italy, ³⁰Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³¹Rheumatology Unit, University of Pisa, Pisa, Italy, Pisa, Italy, ³²Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. México City, Mexico, Mexico, Mexico, ³³Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ³⁴Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³⁵Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic. Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the frequency and characterize the systemic presentation of primary Sjögren syndrome (SjS) out of the ESSDAI classification in a large international, multi-ethnic…
Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
María José Barrera ¹, Sergio Aguilera², Patricia Carvajal ³, Isabel Castro ⁴, Sergio González ⁵, Claudio Molina ¹, Soledad Matus ⁶, Daniela Jara ³ and María Julieta González ³, ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Clínica INDISA, Santiago, Chile, ³ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁴Departamento Tecnología Médica, Universidad de Chile, Santiago, Chile, ⁵Escuela de Odontología, Universidad Mayor, Santiago, Chile, ⁶Fundación Ciencia & Vida, Santiago, Chile, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…
Abstract Number: 2437 • 2019 ACR/ARP Annual Meeting
Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253
Cheng-Han Wu¹, Ko Jen Li ², Chia-Li Yu ³ and Song-Chou Hsieh ³, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²National Taiwan University Hospital, Taipei, Taiwan (Republic of China), ³Division of Immunology,Rheumatology and Allergy, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: Primary Sjögren's syndrome (SS) is a chronic autoimmune epithelitis characterized by the presence of autoantibodies against SS-related antigen A (SSA) and lymphocytic infiltration of…
Abstract Number: 1462 • 2019 ACR/ARP Annual Meeting
Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study
Jolien van Nimwegen¹, Karin van der Tuuk ¹, Sylvia Liefers ¹, Gwenny Verstappen ¹, Robin Wijnsma ¹, Harry Hollema ¹, Marian Mourits ¹, Hendrika Bootsma ² and Frans Kroese ¹, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University of Groningen, Groningen, Netherlands
Background/Purpose: Women with primary Sjögren’s syndrome (pSS) often experience vaginal dryness, but the pathogenesis of this symptom is unknown. Previously, we reported impaired vaginal health…
Abstract Number: 2419 • 2019 ACR/ARP Annual Meeting
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
Elodie Rivière¹, Juliette Pascaud ², Audrey Paoletti ³, Bineta Ly ³, Gaetane Nocturne ⁴ and Xavier Mariette ⁵, ¹IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, ²IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, ³IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ⁵Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is an auto-immune disorder characterized by a chronic hyperactivation of B lymphocytes. We previously showed that salivary gland epithelial cells…
Abstract Number: 2438 • 2019 ACR/ARP Annual Meeting
Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells
Harini Bagavant ¹, Joanna Papinska ¹, Marta Trzeciak ², Indranil Biswas ¹, Nataliya Smith ², Debra Saunders ², Rheal Towner ² and Umesh Deshmukh¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: The presence of autoantibodies reactive against the Ro52/TRIM21 protein is a hallmark of Sjögren’s syndrome. We have reported that Ro52-immunized mice develop IgG deposits…
Abstract Number: 84 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Estelle Gerossier ¹, Saba Nayar ², Charlotte Smith ², Sylvie Froidevaux ³, Francesca Barone ² and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, ²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ³Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
Abstract Number: 1466 • 2019 ACR/ARP Annual Meeting
Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome
Naoto Azuma¹, Yoshinori Katada ², Aki Nishioka ³, Masahiro Sekiguchi ⁴, Masayasu Kitano ⁵, Sachie Kitano ¹, Hajime Sano ⁶ and Kiyoshi Matsui ¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology, Sakai City Medical Center, Sakai, Japan, ³Department of Rheumatology, Nishinomiya Watanabe Hospital, Nishinomiya, Japan, ⁴Departement of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan, ⁵Department of Rheumatology, Kyoto Okamoto Memorial Hospital, Kumiyama, Japan, ⁶Kyoto Okamoto Memorial Hospital, Kumiyama, Japan
Background/Purpose: In addition to xerostomia symptoms, patients with Sjögren’s syndrome (SS) experience pain and discomfort in the oral cavity, and difficulties in speaking and eating,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.